Decision Resources, a research and consultative firm for pharmaceutical and healthcare issues, offers analysis on the latest developments in the non-small-cell lung cancer drug market.
According to the interviewed thought leaders and based on clinical data, by combining nanoparticle paclitaxel such as Celgene’s Abraxane with carboplatin, which is Bristol-Myers Squibb’s Paraplatin, generics, the first-line advanced squamous non-small-cell lung cancer can earn the proprietary clinical gold standard status of Decision Resources in 2015. Nanoparticle paclitaxel was introduced in 2012 for indication.
Nanoparticle paclitaxel has high-efficacy capabilities. When combined with carboplatin, it is capable of promoting the existing proprietary clinical gold standard of Decision Resources such as gemcitabine, which is Eli Lilly’s Gemzar, generics, and carboplatin.
According to the views of managed care organization (MCO) pharmacy directors and U.S. oncologists stated in Decision Resources’ analysis of the non-small-cell lung cancer drug market, increase in overall survival is one of the reasons responsible for their conclusions in prescribing and formulary status regarding first-line advanced squamous non-small-cell lung cancer.
Interviewed thought leaders and clinical data indicate that nanoparticle paclitaxel, when combined with carboplatin, ipilimumab, integrated with paclitaxel or carboplatin, and necitumumab (ImClone Systems/Bristol-Myers Squibb), with gemcitabine or cisplatin is more effective than the commercial gemcitabine/carboplatin.
The findings state than, in spite of the generic decline of multiple key agents treating the disease, the market of non-small-cell lung cancer drug will grow from $4.2 B in 2010 to $5.4 B in 2020. The countries witnessing expansion include the United Kingdom, the United States, France, Spain, Germany, Italy and Japan. However, there will be a slump in drug sales for metastatic or advanced squamous cell non-small-cell lung cancer from 17% in 2010 to around 13% in 2020.
Source: http://decisionresources.com/